{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:45:39Z","timestamp":1792043139943,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02230-6","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:01:56Z","timestamp":1791997316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering long-acting injectable in situ forming implants for sustained delivery of citalopram in depression management"],"prefix":"10.1007","author":[{"given":"Haripriya","family":"Koppisetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Nakmode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weranga","family":"Rajapaksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souha","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2230_CR1","unstructured":"(WHO), W.H.O. Depressive Disorder (Depression). 2026 [cited 2026 15 May]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"2230_CR2","doi-asserted-by":"crossref","first-page":"115958","DOI":"10.1016\/j.psychres.2024.115958","volume":"337","author":"G Yan","year":"2024","unstructured":"Yan G, et al. Global, regional, and national temporal trend in burden of major depressive disorder from 1990 to 2019: An analysis of the global burden of disease study. Psychiatry Res. 2024;337:115958.","journal-title":"Psychiatry Res"},{"issue":"11","key":"2230_CR3","doi-asserted-by":"crossref","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","volume":"10","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari AJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547.","journal-title":"PLoS Med"},{"key":"2230_CR4","doi-asserted-by":"crossref","unstructured":"Lochmann D, Richardson T. Selective serotonin reuptake inhibitors. Antidepressants: From biogenic amines to new mechanisms of action. Springer; 2019. pp. 135\u201344.","DOI":"10.1007\/164_2018_172"},{"key":"2230_CR5","unstructured":"Shoar NS, Fariba KA, Padhy RK. Citalopram, in StatPearls [Internet]. StatPearls Publishing; 2023."},{"issue":"10","key":"2230_CR6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2215-0366(23)00176-1","volume":"10","author":"D Papola","year":"2023","unstructured":"Papola D, et al. Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders. Lancet Psychiatry. 2023;10(10):809\u201316.","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"2230_CR7","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0149-2918(03)80220-5","volume":"25","author":"PS Masand","year":"2003","unstructured":"Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289\u2013304.","journal-title":"Clin Ther"},{"issue":"2","key":"2230_CR8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4274\/tjps.galenos.2020.49799","volume":"18","author":"NR Marasine","year":"2021","unstructured":"Marasine NR, Sankhi S. Factors associated with antidepressant medication non-adherence. Turkish J Pharm Sci. 2021;18(2):242.","journal-title":"Turkish J Pharm Sci"},{"key":"2230_CR9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2018.07.020","volume":"202","author":"RE Nielsen","year":"2018","unstructured":"Nielsen RE, et al. Second-generation LAI are associated to favorable outcome in a cohort of incident patients diagnosed with schizophrenia. Schizophr Res. 2018;202:234\u201340.","journal-title":"Schizophr Res"},{"key":"2230_CR10","unstructured":"Consta R. Precribing information. 2003."},{"key":"2230_CR11","unstructured":"Perseris. Patient information. [cited 2026 28 May]; Available from: https:\/\/www.perseris.com\/"},{"key":"2230_CR12","unstructured":"Sustenna I. Patient information. [cited 2026 28 May]; Available from: https:\/\/www.safetyandquality.gov.au\/medicine-finder\/invega-sustenna-suspension-for-injection"},{"key":"2230_CR13","unstructured":"Relprevv Z. Patient Information."},{"issue":"4","key":"2230_CR14","doi-asserted-by":"crossref","first-page":"e0267808","DOI":"10.1371\/journal.pone.0267808","volume":"17","author":"L Lian","year":"2022","unstructured":"Lian L, et al. Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review. PLoS ONE. 2022;17(4):e0267808.","journal-title":"PLoS ONE"},{"issue":"6","key":"2230_CR15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/mp500070m","volume":"11","author":"JF Remenar","year":"2014","unstructured":"Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm. 2014;11(6):1739\u201349.","journal-title":"Mol Pharm"},{"key":"2230_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2015.11.014","volume":"220","author":"A Fakhari","year":"2015","unstructured":"Fakhari A, Subramony JA. Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. J Controlled Release. 2015;220:465\u201375.","journal-title":"J Controlled Release"},{"issue":"2","key":"2230_CR17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","volume":"161","author":"S Kempe","year":"2012","unstructured":"Kempe S, M\u00e4der K. In situ forming implants\u2014an attractive formulation principle for parenteral depot formulations. J Controlled Release. 2012;161(2):668\u201379.","journal-title":"J Controlled Release"},{"key":"2230_CR18","doi-asserted-by":"crossref","unstructured":"Kanwar N, Sinha VR. In situ forming depot as sustained-release drug delivery systems. Crit Reviews\u2122 Therapeutic Drug Carrier Syst, 2019. 36(2):93-136","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025013"},{"key":"2230_CR19","doi-asserted-by":"publisher","unstructured":"Patil RR, et al. Exploring the Transformative Potential of. Situ Gels: An Overview of Thermosensitive and pH-Sensitive Gel Systems for Biomedical Applications. in Macromolecular Symposia. Wiley Online Library; 2024.413, 2300153 https:\/\/doi.org\/10.1002\/masy.202300153","DOI":"10.1002\/masy.202300153"},{"issue":"1","key":"2230_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0972-124X.94603","volume":"16","author":"MA Javali","year":"2012","unstructured":"Javali MA, Vandana K. A comparative evaluation of atrigel delivery system (10% doxycycline hyclate) Atridox with scaling and root planing and combination therapy in treatment of periodontitis: A clinical study. J Indian Soc Periodontology. 2012;16(1):43\u20138.","journal-title":"J Indian Soc Periodontology"},{"issue":"3","key":"2230_CR21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1590\/s1677-5538.ibju.2019.0212","volume":"46","author":"CSd Freitas","year":"2020","unstructured":"Freitas CSd, Soares AN. Efficacy of Leuprorelide acetate (Eligard\u00ae) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer. Int braz j urol. 2020;46(3):383\u20139.","journal-title":"Int braz j urol"},{"issue":"1","key":"2230_CR22","first-page":"74","volume":"1","author":"K Malik","year":"2010","unstructured":"Malik K, et al. Atrigel: A potential parenteral controlled drug delivery system. Der Pharmacia Sinica. 2010;1(1):74\u201381.","journal-title":"Der Pharmacia Sinica"},{"issue":"1","key":"2230_CR23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4155\/tde.14.91","volume":"6","author":"DN Kapoor","year":"2015","unstructured":"Kapoor DN, et al. PLGA: a unique polymer for drug delivery. Therapeutic delivery. 2015;6(1):41\u201358.","journal-title":"Therapeutic delivery"},{"issue":"11","key":"2230_CR24","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1002\/aic.15282","volume":"62","author":"Y Ji","year":"2016","unstructured":"Ji Y, et al. Drug release kinetics and mechanism from PLGA formulations. AIChE J. 2016;62(11):4055\u201365.","journal-title":"AIChE J"},{"issue":"4","key":"2230_CR25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40005-013-0072-5","volume":"43","author":"S Amatya","year":"2013","unstructured":"Amatya S, et al. Drug release testing methods of polymeric particulate drug formulations. J Pharm Invest. 2013;43(4):259\u201366.","journal-title":"J Pharm Invest"},{"issue":"1","key":"2230_CR26","first-page":"204925","volume":"2014","author":"J Zuo","year":"2014","unstructured":"Zuo J, et al. Evaluation of the DDSolver software applications. Biomed Res Int. 2014;2014(1):204925.","journal-title":"Biomed Res Int"},{"issue":"2","key":"2230_CR27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123\u201333.","journal-title":"Eur J Pharm Sci"},{"key":"2230_CR28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpba.2017.11.065","volume":"150","author":"Y Sun","year":"2018","unstructured":"Sun Y, et al. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV\u2013vis imaging. J Pharm Biomed Anal. 2018;150:95\u2013106.","journal-title":"J Pharm Biomed Anal"},{"key":"2230_CR29","doi-asserted-by":"crossref","unstructured":"Ahmed TA et al. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. Drug design, development and therapy, 2016: pp. 405\u2013415.","DOI":"10.2147\/DDDT.S98078"},{"issue":"3","key":"2230_CR30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jconrel.2010.08.020","volume":"147","author":"RB Patel","year":"2010","unstructured":"Patel RB, et al. Effect of injection site on in situ implant formation and drug release in vivo. J Controlled Release. 2010;147(3):350\u20138.","journal-title":"J Controlled Release"},{"issue":"6","key":"2230_CR31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/pharmaceutics17060750","volume":"17","author":"EO Bakhrushina","year":"2025","unstructured":"Bakhrushina EO, et al. Phase-inversion in situ systems: problems and prospects of biomedical application. Pharmaceutics. 2025;17(6):750.","journal-title":"Pharmaceutics"},{"issue":"5","key":"2230_CR32","doi-asserted-by":"crossref","first-page":"103717","DOI":"10.1016\/j.xphs.2025.103717","volume":"114","author":"LK Vora","year":"2025","unstructured":"Vora LK, et al. In-situ forming solvent-induced phase inversion implants for controlled drug delivery: role of hydrophilic polymers. J Pharm Sci. 2025;114(5):103717.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2230_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1208\/s12249-021-01965-4","volume":"22","author":"J Kozak","year":"2021","unstructured":"Kozak J, Rabiskova M, Lamprecht A. Muscle tissue as a surrogate for in vitro drug release testing of parenteral depot microspheres. AAPS PharmSciTech. 2021;22(3):119.","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"2230_CR34","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s13346-025-01892-y","volume":"15","author":"DD Nakmode","year":"2025","unstructured":"Nakmode DD, et al. Development of an in-situ forming implant system for levodopa and carbidopa for the treatment of parkinson\u2019s disease. Drug Delivery Translational Res. 2025;15(11):4026\u201342.","journal-title":"Drug Delivery Translational Res"},{"key":"2230_CR35","doi-asserted-by":"crossref","unstructured":"Rignall A. ICHQ1A (R2) stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms. ICH quality guidelines: an implementation guide, 2017: pp. 3\u201344.","DOI":"10.1002\/9781118971147.ch1"},{"key":"2230_CR36","unstructured":"Riss TL, et al. Cell viability assays. Assay guidance manual [Internet]; 2016."},{"issue":"2","key":"2230_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-004-2006-4","volume":"178","author":"FE Lotrich","year":"2005","unstructured":"Lotrich FE, et al. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology. 2005;178(2):268\u201375.","journal-title":"Psychopharmacology"},{"key":"2230_CR38","unstructured":"Prochymal. Product Monogrpah PROCHYMAL Adult Human Mesenchymal Stem Cells (hMSCs) 2014."},{"key":"2230_CR39","unstructured":"(CDER), U.S.D.o.H.a.H.S.F.a.D.A.C.f.D.E.a.R., Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005."},{"key":"2230_CR40","doi-asserted-by":"crossref","unstructured":"Borman P, Elder D. Q2 (R1) validation of analytical procedures: text and methodology. ICH quality guidelines: an implementation guide, 2017: pp. 127\u2013166.","DOI":"10.1002\/9781118971147.ch5"},{"key":"2230_CR41","doi-asserted-by":"crossref","first-page":"113912","DOI":"10.1016\/j.addr.2021.113912","volume":"178","author":"X Wang","year":"2021","unstructured":"Wang X, Burgess DJ. Drug release from in situ forming implants and advances in release testing. Adv Drug Deliv Rev. 2021;178:113912.","journal-title":"Adv Drug Deliv Rev"},{"key":"2230_CR42","unstructured":"Price G, Patel DA. Drug bioavailability. StatPearls [Internet]. StatPearls Publishing; 2023.Treasure Island (FL): StatPearls Publishing; 2023 Jan\u2013. PMID: 32496732. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557852\/"},{"issue":"6","key":"2230_CR43","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/cben.202300027","volume":"10","author":"M Askarizadeh","year":"2023","unstructured":"Askarizadeh M, et al. Kinetic modeling to explain the release of medicine from drug delivery systems. ChemBioEng Reviews. 2023;10(6):1006\u201349.","journal-title":"ChemBioEng Reviews"},{"key":"2230_CR44","doi-asserted-by":"crossref","unstructured":"Talevi A, Ruiz ME. Korsmeyer-peppas, peppas-sahlin, and brazel-peppas: models of drug release. The ADME encyclopedia: A comprehensive guide on biopharmacy and pharmacokinetics. Springer; 2022. pp. 613 \u201321.","DOI":"10.1007\/978-3-030-84860-6_35"},{"key":"2230_CR45","doi-asserted-by":"crossref","unstructured":"Jahromi LP et al. A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles. Heliyon, 2020. 6(2).","DOI":"10.1016\/j.heliyon.2020.e03451"},{"key":"2230_CR46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.colsurfa.2012.04.040","volume":"409","author":"SS Dukhin","year":"2012","unstructured":"Dukhin SS, Labib ME. Theory of effective drug release from medical implants based on the Higuchi model and physico-chemical hydrodynamics. Colloids Surf A. 2012;409:10\u201320.","journal-title":"Colloids Surf A"},{"issue":"1","key":"2230_CR47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/pharmaceutics16010115","volume":"16","author":"EO Bakhrushina","year":"2024","unstructured":"Bakhrushina EO, et al. Burst release from in situ forming PLGA-based implants: 12 effectors and ways of correction. Pharmaceutics. 2024;16(1):115.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2230_CR48","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","volume":"172","author":"M Parent","year":"2013","unstructured":"Parent M, et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J Controlled Release. 2013;172(1):292\u2013304.","journal-title":"J Controlled Release"},{"key":"2230_CR49","doi-asserted-by":"crossref","first-page":"106253","DOI":"10.1016\/j.ejps.2022.106253","volume":"178","author":"J Wilkinson","year":"2022","unstructured":"Wilkinson J, et al. Lipid based intramuscular long-acting injectables: Current state of the art. Eur J Pharm Sci. 2022;178:106253.","journal-title":"Eur J Pharm Sci"},{"key":"2230_CR50","unstructured":"Bank D. Citalopram. 2025 [cited 2025 30 July]; Available from: https:\/\/go.drugbank.com\/drugs\/DB00215"},{"key":"2230_CR51","doi-asserted-by":"crossref","first-page":"122313","DOI":"10.1016\/j.ijpharm.2022.122313","volume":"628","author":"C Zhang","year":"2022","unstructured":"Zhang C, Bodmeier R. A comparative study of PLGA microparticle properties loaded with micronized, nanosized or dissolved drug. Int J Pharm. 2022;628:122313.","journal-title":"Int J Pharm"},{"issue":"11","key":"2230_CR52","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/pharmaceutics14112264","volume":"14","author":"A Akram","year":"2022","unstructured":"Akram A, et al. How to improve solubility and dissolution of irbesartan by fabricating ternary solid dispersions: optimization and in-vitro characterization. Pharmaceutics. 2022;14(11):2264.","journal-title":"Pharmaceutics"},{"issue":"2","key":"2230_CR53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0040-6031(96)02904-8","volume":"285","author":"F Balestrieri","year":"1996","unstructured":"Balestrieri F, et al. Application of differential scanning calorimetry to the study of drug-excipient compatibility. Thermochimica acta. 1996;285(2):337\u201345.","journal-title":"Thermochimica acta"},{"issue":"3","key":"2230_CR54","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s10973-018-7226-7","volume":"133","author":"B Pinto","year":"2018","unstructured":"Pinto B, Ferreira A, Cavalheiro ETG. Thermal degradation mechanism for citalopram and escitalopram. J Therm Anal Calorim. 2018;133(3):1509\u201318.","journal-title":"J Therm Anal Calorim"},{"issue":"1","key":"2230_CR55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jbm.b.31419","volume":"91","author":"HY Tan","year":"2009","unstructured":"Tan HY, et al. Spectroscopy techniques for analyzing the hydrolysis of PLGA and PLLA. J Biomedical Mater Res Part B: Appl Biomaterials. 2009;91(1):433\u201340.","journal-title":"J Biomedical Mater Res Part B: Appl Biomaterials"},{"issue":"3","key":"2230_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00894-025-06300-3","volume":"31","author":"R Shanmugam","year":"2025","unstructured":"Shanmugam R, et al. Monomer, cyclic dimer of dimethyl sulfoxide, and dimethyl sulfoxide-water hydrogen bonded complexes: FTIR studies and quantum chemical calculations. J Mol Model. 2025;31(3):85.","journal-title":"J Mol Model"},{"key":"2230_CR57","doi-asserted-by":"crossref","unstructured":"Khairuddin et al. FTIR studies on the effect of concentration of polyethylene glycol on polimerization of Shellac. in Journal of Physics: Conference Series. 2016. IOP Publishing.","DOI":"10.1088\/1742-6596\/776\/1\/012053"},{"issue":"1","key":"2230_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10103-024-04050-x","volume":"39","author":"S Deekshitha","year":"2024","unstructured":"Deekshitha S, et al. Spectroscopic evaluation of sesame and mustard oils treated with Murchana method. Lasers Med Sci. 2024;39(1):99.","journal-title":"Lasers Med Sci"},{"issue":"2","key":"2230_CR59","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1208\/s12249-011-9625-y","volume":"12","author":"F Cilurzo","year":"2011","unstructured":"Cilurzo F, et al. Injectability evaluation: an open issue. AAPS PharmSciTech. 2011;12(2):604\u20139.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"2230_CR60","doi-asserted-by":"crossref","first-page":"1901521","DOI":"10.1002\/adhm.201901521","volume":"9","author":"TE Robinson","year":"2020","unstructured":"Robinson TE, et al. Filling the gap: a correlation between objective and subjective measures of injectability. Adv Healthc Mater. 2020;9(5):1901521.","journal-title":"Adv Healthc Mater"},{"key":"2230_CR61","doi-asserted-by":"crossref","first-page":"115003","DOI":"10.1016\/j.addr.2023.115003","volume":"200","author":"AK Pandya","year":"2023","unstructured":"Pandya AK, et al. Polymeric in situ forming depots for long-acting drug delivery systems. Adv Drug Deliv Rev. 2023;200:115003.","journal-title":"Adv Drug Deliv Rev"},{"key":"2230_CR62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2018.03.003","volume":"276","author":"Q Bao","year":"2018","unstructured":"Bao Q, et al. In vitro and ex vivo correlation of drug release from ophthalmic ointments. J Controlled Release. 2018;276:93\u2013101.","journal-title":"J Controlled Release"},{"issue":"16","key":"2230_CR63","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.3390\/ijms22168884","volume":"22","author":"A Butreddy","year":"2021","unstructured":"Butreddy A, et al. PLGA\/PLA-based long-acting injectable depot microspheres in clinical use: production and characterization overview for protein\/peptide delivery. Int J Mol Sci. 2021;22(16):8884.","journal-title":"Int J Mol Sci"},{"key":"2230_CR64","unstructured":"Administration, U.S.F.a.D., USP\u2009<\u20091\u2009>\u2009Injections and Implanted Drug Products and general drug product specification ICH Q6A. 2026."},{"key":"2230_CR65","unstructured":"Agency EM. SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT. European Medical Agency; 1992."},{"key":"2230_CR66","doi-asserted-by":"crossref","unstructured":"Theiszov\u00e1 M, et al. Comparison the cytotoxicity of hydroxiapatite measured by direct cell counting and MTT test in murine fibroblast NIH-3T3 cells. Volume 149. Biomedical Papers-Palacky University in Olomouc; 2005. p. 393. 2.","DOI":"10.5507\/bp.2005.066"},{"issue":"10","key":"2230_CR67","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/1087057115605765","volume":"20","author":"A Single","year":"2015","unstructured":"Single A, et al. A comparison of real-time and endpoint cell viability assays for improved synthetic lethal drug validation. J BioMol Screen. 2015;20(10):1286\u201393.","journal-title":"J BioMol Screen"},{"issue":"5","key":"2230_CR68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00007691-200310000-00010","volume":"25","author":"Y Le Bloc\u2019h","year":"2003","unstructured":"Le Bloc\u2019h Y, et al. Routine therapeutic drug monitoring in patients treated with 10\u2013360\u00a0mg\/day citalopram. Ther Drug Monit. 2003;25(5):600\u20138.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2230_CR69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2010.05.005","volume":"146","author":"SC Owen","year":"2010","unstructured":"Owen SC, et al. Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft. J Controlled Release. 2010;146(1):23\u201330.","journal-title":"J Controlled Release"},{"issue":"9","key":"2230_CR70","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1021\/mp5002813","volume":"11","author":"E Sj\u00f6gren","year":"2014","unstructured":"Sj\u00f6gren E, et al. Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model. Mol Pharm. 2014;11(9):3097\u2013111.","journal-title":"Mol Pharm"},{"issue":"5","key":"2230_CR71","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/ph18050631","volume":"18","author":"H Omidian","year":"2025","unstructured":"Omidian H, Wilson RL. PLGA implants for controlled drug delivery and regenerative medicine: advances, challenges, and clinical potential. Pharmaceuticals. 2025;18(5):631.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2230_CR72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/03639045.2013.850706","volume":"41","author":"G Singhvi","year":"2015","unstructured":"Singhvi G, et al. Prediction of in vivo plasma concentration\u2013time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method. Drug Dev Ind Pharm. 2015;41(1):105\u20138.","journal-title":"Drug Dev Ind Pharm"},{"issue":"8","key":"2230_CR73","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jcph.1842","volume":"61","author":"R Gomeni","year":"2021","unstructured":"Gomeni R, Bressolle-Gomeni F. Modeling complex pharmacokinetics of long\u2010acting injectable products using convolution\u2010based models with nonparametric input functions. J Clin Pharmacol. 2021;61(8):1081\u201395.","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02230-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:56:26Z","timestamp":1792040186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02230-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":73,"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02230-6","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No animals were used in the study. Ex vivo study was performed using pig muscle collected from the local butcher house with approval from Animal ethics committee from university to use scavenged tissues for studies.","order":1,"name":"Ethics","label":"Ethics approval and consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}